BANGALORE, India , May 23, 2025 /PRNewswire/ — Acne Medicine Market is Segmented by Type (OTC, Prescription Medicine), by Application (Topical, Oral).

The Global Acne Medicine revenue was USD 3616.6 Million in 2022 and is forecast to a readjusted size of USD 4273.4 Million by 2029 with a CAGR of 3.4% during the review period (2023-2029).

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-13R16186/Global_and_India_Acne_Medicine_Market

Major Factors Driving the Growth of Acne Medicine Market:

The acne medicine market is experiencing significant growth propelled by rising acne prevalence, evolving skincare routines, and the growing demand for effective, accessible treatments. With options ranging from over-the-counter products to prescription solutions, the market caters to a broad consumer base. Continuous innovation, influencer marketing, and the expansion of telehealth services are reshaping how consumers approach acne management. Moreover, increasing interest in natural formulations and dermatologically tested products is redefining consumer preferences. As dermatology services become more accessible and digital platforms democratize skincare advice, the acne medicine market is expected to witness sustained growth, particularly across urban, youth-centric, and emerging economies.

Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-13R16186/global-and-india-acne-medicine

TRENDS INFLUENCING THE GROWTH OF THE ACNE MEDICINE MARKET:

Prescription medicines play a crucial role in driving the growth of the acne medicine market due to their high efficacy in treating moderate to severe acne. Dermatologists often prescribe topical retinoids, oral antibiotics, or isotretinoin for patients who do not respond to over-the-counter treatments. The increasing awareness among patients regarding the benefits of dermatologist-prescribed treatments has contributed to growing demand. Moreover, insurance coverage in several developed markets encourages patients to opt for prescription medications. The expanding teenage and young adult population suffering from persistent acne has also led to a surge in dermatological consultations, boosting prescription volumes. In addition, innovations in formulation and fewer side effects in newer drugs are enhancing consumer confidence, further accelerating market growth.

Over-the-counter (OTC) acne medications significantly contribute to the expansion of the acne medicine market by providing accessible and affordable solutions. Consumers prefer OTC products due to the convenience of purchase without a prescription and the availability of a wide range of options including gels, creams, face washes, and patches. Ingredients such as benzoyl peroxide, salicylic acid, and alpha hydroxy acids are commonly found in OTC products, offering effective treatment for mild to moderate acne. The rise of e-commerce platforms has made OTC acne solutions easily available to consumers globally, boosting sales. Additionally, aggressive marketing strategies and endorsements from influencers and dermatologists have elevated product visibility, encouraging higher consumer adoption and fueling market growth.

Oral acne medications are propelling market growth due to their effectiveness in treating severe and persistent acne conditions. These include oral antibiotics, hormonal treatments, and isotretinoin, which target internal root causes such as bacterial infections, hormonal imbalances, and sebum production. With increasing diagnosis and awareness of acne’s systemic causes, dermatologists are more likely to prescribe oral treatments. Additionally, the demand for fast and long-term results is driving preference for oral therapies. The pharmaceutical industry’s efforts to improve drug tolerability and reduce side effects have made oral acne medications more acceptable among patients. Furthermore, the rise in adult acne, particularly among women, has increased the prescription of oral hormonal therapies, expanding the overall market.

Advertisement

The growing prevalence of acne, especially among teenagers and young adults, is a key factor driving the acne medicine market. Hormonal changes, stress, dietary patterns, and environmental pollution contribute to acne outbreaks. As awareness of skin health increases, more individuals are actively seeking treatment options. This rising demand fuels product innovation and launches, encouraging manufacturers to develop both preventive and treatment-based medicines. Adult acne, particularly among working women, is also becoming a notable concern, pushing demand for specialized medications and dermatologist consultations. This demographic shift ensures a sustained need for effective acne therapies, thereby accelerating the overall market growth across both prescription and OTC segments.

Improved access to dermatology services and clinics is significantly influencing the acne medicine market. In both developed and developing economies, the number of dermatologists and specialized skincare centers is increasing. Government initiatives, insurance coverage, and urbanization are enhancing access to treatment. Additionally, teledermatology and online consultations have emerged as viable options for people in remote locations, further expanding the reach of acne treatments. The availability of professional guidance leads to increased prescriptions, higher treatment adherence, and more usage of both oral and topical medications. As healthcare infrastructure strengthens, especially in emerging markets, the demand for acne medicines continues to rise.

The rising emphasis on personal grooming and aesthetic appearance, particularly among younger populations, is boosting demand for acne solutions. Social media and digital influence are driving awareness about clear skin as a beauty standard, leading to increased spending on skincare products. Educational campaigns by brands, along with dermatologist-backed content, have contributed to de-stigmatizing acne while promoting proactive treatment. Consumers are becoming more knowledgeable about product ingredients and their effects, leading to demand for scientifically backed and dermatologically tested medicines. As people seek long-term solutions rather than quick fixes, the market is witnessing a surge in sustained usage of acne therapies.

There is a noticeable shift in consumer preferences toward natural and clean-label acne medications. Increasing awareness about the long-term impact of chemical-based products and concerns over skin sensitivity have pushed demand for safer, plant-based alternatives. Herbal formulations using tea tree oil, aloe vera, witch hazel, and green tea are becoming popular among eco-conscious consumers. Companies are responding by launching certified, cruelty-free, and non-toxic product lines, aligning with the values of sustainability and wellness. This trend is opening new growth avenues, especially in the premium segment, contributing to the diversification of the acne medicine market landscape.

Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-13R16186&lic=single-user

ACNE MEDICINE MARKET SHARE:

Global core acne medicine manufacturers include Galderma, Bausch Health, Teva etc.The top 3 companies hold a share of about 50%.

North America is the largest market, with a share of about 50%, followed by Europe and Asia Pacific with the share of about 25% and 15%.North America leads due to high awareness, dermatologist availability, and product innovation. Asia-Pacific shows rapid growth driven by a large youth population, increasing urbanization, and rising income levels. Europe benefits from robust healthcare systems and increasing cosmetic concerns.

In terms of product, prescription medicine is the largest segment, with a share over 77%.

And in terms of application, the largest application is topical, followed by oral.

Advertisement

Key Companies:

• Galderma
• Galderma S A
• Bausch Health
• TEVA
• GlaxoSmithKline PLC
• Mylan NV
• Almirall
• Sun Pharma
• Mayne Pharma
• Lion
• HUAPONT
• Sine Pharma

Inquire for Discount: https://reports.valuates.com/request/discount/QYRE-Auto-13R16186/global-and-india-acne-medicine 

SUBSCRIPTION

We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.

DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!

–          Acne Products Market
–          Baby Acne Medicine Market
–          The global Oral Acne Medicine market was valued at USD 929.9 Million in 2023 and is anticipated to reach USD 1144.1 Million by 2030, witnessing a CAGR of 3.0% during the forecast period 2024-2030.
–          Consumer Acne Medicine Market
–          The global market for Topical Acne Medication was estimated to be worth USD 2685.7 Million in 2023 and is forecast to a readjusted size of USD 4015.4 Million by 2030 with a CAGR of 6.0% during the forecast period 2024-2030
–          The global market for Acne Drugs was estimated to be worth USD 3616.6 Million in 2023 and is forecast to a readjusted size of USD 4592.8 Million by 2030 with a CAGR of 3.4% during the forecast period 2024-2030.
–          LED Light Therapy Face Masks Market
–          Anti-acne Dermal Patch Market
–          Dissolvable Microneedle Patches market was valued at USD 485 Million in 2023 and is anticipated to reach USD 747 Million by 2030, witnessing a CAGR of 6.8% during the forecast period 2024-2030.
–          The global market for Cosmetics Microneedle Patches was valued at USD 472 Million in the year 2024 and is projected to reach a revised size of USD 748 Million by 2031, growing at a CAGR of 6.9% during the forecast period.
–          Moderate To Severe Acne Therapeutics Market

DISCOVER OUR VISION: VISIT ABOUT US!

Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.

Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.

To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.

GET A FREE QUOTE

Advertisement

Valuates Reports
[email protected]
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335

Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753

https://www.facebook.com/valuateskorean
https://www.facebook.com/valuatesspanish
https://www.facebook.com/valuatesjapanese
https://valuatesreportspanish.blogspot.com/
https://valuateskorean.blogspot.com/
https://valuatesgerman.blogspot.com/
https://valuatesreportjapanese.blogspot.com/ 

Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/acne-medicine-market-to-reach-usd-4-27-billion-by-2029–key-trends-in-otc–prescription-segments-revealed–valuates-reports-302464362.html

SAN FRANCISCO, May 23, 2025 /PRNewswire/ — Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has expanded its global footprint with the launch of its Institute of Foundation Models (IFM). The IFM is a multi-site initiative consisting of a newly established Silicon Valley Lab in Sunnyvale, CA, combined with previously announced lab facilities in Paris and Abu Dhabi.

The launch event yesterday at the Computer History Museum in Mountain View, establishes the third node in its global research network. This strategic expansion connects the university with California’s vibrant ecosystem of AI researchers, startups, and tech companies.

For the UAE and MBZUAI, this move represents another strategic step in the country’s long-term economic diversification plan. By investing in cutting-edge technologies like advanced AI foundation models, the UAE continues to build knowledge-based sectors to support its long-term economic and social transformation efforts.

“Today’s launch of the IFM represents a major step forward for the collaboration and global development of frontier-class AI foundation models,” said Professor Eric Xing, President and University Professor, MBZUAI. “Our expansion into Silicon Valley provides a critical footprint to grow our presence in one of the most vibrant AI ecosystems in the world. We’re creating pathways for knowledge exchange with leading institutions and accessing a talent pool that understands how to scale research into real-world applications.”

The launch event drew representatives from the world’s leading AI companies and academic institutions, highlighting the growing interest in MBZUAI’s global approach to foundation model research.

At the heart of MBZUAI’s demonstrations was PAN, a world model capable of infinite simulations of diverse realities ranging from basic physical interactions to complex agent scenarios.

Unlike previous systems focused primarily on generating text, audio, or images, PAN predicts comprehensive world states by integrating multimodal inputs like language, video, spatial data, and physical actions. This enables advanced reasoning, strategic planning, and nuanced decision-making for applications from autonomous driving to robotics.

PAN’s innovative hierarchical architecture supports multi-level reasoning and real-time interaction within simulations, maintaining high accuracy over extended scenarios. Its companion, PAN-Agent, showcases its utility in multimodal reasoning tasks, such as mathematics and coding, within dynamic simulated environments.

Advertisement

K2 and JAIS: Advanced Foundation Models with Global Impact

The IFM lab is also advancing two flagship AI systems demonstrating the commitment to further advance frontier-class foundation models: K2 and JAIS.

A soon to be released update to K2-65B will focus on delivering breakthrough reasoning capabilities with sustainable performance.

JAIS stands as the world’s most advanced Arabic large language model. At the IFM JAIS will continue to expand in capability with increased language support and add more context to preserve and promote the cultures it supports.

Building AI in the Open: Transparency as a Core Value

MBZUAI has established one of the industry’s most transparent approaches to AI development, open-sourcing not just models but entire development processes—positioning IFM as a leader in building openly. The LLM360 initiative provides researchers with complete materials including training code, datasets, and model checkpoints. This openness is balanced with safeguards including international advisory boards and peer review processes that maintain research integrity.

The IFM’s structure includes dedicated teams focused on model architecture, training methods, evaluation frameworks, and safety systems—combining the agility of a startup with the resources of an established research institution.

About Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) 

MBZUAI is a research-focused university in Abu Dhabi, and the first university dedicated entirely to the advancement of science through AI. For more information, visit www.mbzuai.ac.ae. 

For press inquiries:
Aya Sakoury 
Head of PR and Strategic Communications
[email protected] 

Advertisement

Photo: https://mma.prnewswire.com/media/2695164/MBZUAI.jpg

View original content:https://www.prnewswire.co.uk/news-releases/mbzuai-launches-institute-of-foundation-models-and-establishes-silicon-valley-ai-lab-302464311.html

Equity Insider News Commentary

Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, May 23, 2025 /PRNewswire/ — Equity Insider News Commentary – A new report from Philips reveals a growing divide between doctors and patients when it comes to AI in healthcare. While 63% of surveyed healthcare professionals believe AI can help improve outcomes, only 48% of patients share that optimism. As researchers explore what’s needed for successful AI adoption in healthcare, major players in tech and biotech are already moving ahead—recent updates have come from Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Certara, Inc. (NASDAQ: CERT), CareCloud, Inc. (NASDAQ: CCLD), and Microsoft Corporation (NASDAQ: MSFT).

Analysts at MarketsandMarkets expect the AI healthcare sector to grow at a 38.6% CAGR, topping $110 billion by 2030. Accenture goes even further, estimating AI could inject another $461 billion in added value by 2035—amplifying impact across a global healthcare system already on track to surpass $2.26 trillion.

Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is positioning its Vision AI platform at the forefront of predictive healthcare. The company is in advanced discussions to acquire or exclusively license a patented early disease detection technology that could significantly enhance its diagnostic capabilities. If finalized, the deal would allow Vision AI to generate clinical insights even in the absence of a complete patient dataset—unlocking earlier intervention opportunities and supporting a more proactive model of care.

“Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,” said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC), said of AAC’s aim to continue to add to its portfolio. “We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.”

The potential acquisition aligns with Avant and Ainnova’s shared mission to deliver scalable, preventive health tools that merge retinal imaging, vital sign monitoring, and machine learning into one streamlined platform. Vision AI is already positioned as a next-generation diagnostic engine for chronic conditions like diabetes, cardiovascular disease, and kidney dysfunction. Now, the joint venture is pushing further—evaluating breakthrough technologies that could detect emerging health issues at a pre-symptomatic stage.

Recent platform updates saw four proprietary algorithms—trained on over 2.3 million real-world clinical cases—fully integrated into Vision AI. The addition of new IP from this proposed deal would mark a significant leap forward, enabling predictive models to extract meaningful signals from even limited patient data.

Avant and Ainnova view this initiative as part of a broader strategy to consolidate breakthrough tools that make early disease detection more scalable, mobile, and applicable across diverse healthcare settings. While a final agreement has yet to be announced, the companies have stated they will keep shareholders informed as developments progress.

In parallel, Avant has entered formal discussions to acquire Ainnova outright—building on their existing alignment under the Ai-nova Acquisition Corp. (AAC) structure. The timing is deliberate, coming just ahead of a planned FDA pre-submission meeting this July. A completed merger would unify operations, reduce internal complexity, and bolster the joint venture’s regulatory readiness as it prepares for potential U.S. market entry.

Advertisement

“We believe bringing the two companies together will offer tremendous value for shareholders,” said Vargas. “It will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally.”

At the center of this initiative is Vision AI—a non-invasive screening platform that integrates retinal imaging, vital sign monitoring, and machine-learning models to flag early indicators of chronic disease. The system targets conditions such as diabetic retinopathy, cardiovascular issues, kidney and liver disorders, and type 2 diabetes. Operated under the AAC structure, the joint venture holds global rights to Vision AI, which has demonstrated over 90% sensitivity in early detection based on research cited by the NIH.

“This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market,” said Vargas. “Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product.”

While many AI healthcare platforms remain stuck in pilot stages, Avant’s Vision AI is already live across multiple Latin American markets—including Chile, Mexico, and Brazil—where it’s actively being used in clinical settings. These real-world deployments are generating essential data on safety and efficacy, while also providing user feedback that guides ongoing system improvements.

To broaden its diagnostic reach, the Ai-nova joint venture recently integrated four additional algorithms into the platform. Each was trained on a dataset of more than 2.3 million clinical records, enhancing Vision AI’s precision across a wider spectrum of chronic diseases. With active momentum abroad and U.S. regulatory discussions now underway, Avant’s trajectory appears to be moving from early validation toward broader market penetration.

CONTINUED… Read this and more news for Avant Technologies at:

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

Renovaro Inc. (NASDAQ: RENB) has officially launched Augusta, a next-generation AI-powered platform targeting precision neurology. Designed for patient stratification, biomarker discovery, and accelerated drug development, Augusta integrates multiomics, contingent AI, phenoclustering, and in silico screening into one modular system.

“The Augusta platform is about validation,” said David Weinstein, CEO of Renovaro Inc. “We’re setting a new bar for how AI can be responsibly and effectively deployed in clinical and experimental settings.”

The platform has already demonstrated early success in Parkinson’s disease and epilepsy, with expansion plans underway for additional neurological conditions.

Advertisement

Certara, Inc. (NASDAQ: CERT) has launched its Non-Animal Navigator™ solution to help drug developers reduce reliance on animal testing, aligning with the FDA’s Roadmap to Reducing Animal Testing in Preclinical Safety Studies.

“The FDA announcement and roadmap pave the way for more model-informed drug development approaches that are predictive, efficient, and ethical,” said William F. Feehery, CEO of Certara Inc. “It is part of a growing industry adoption trend to use scientifically robust new approach methodologies (NAMs) like AI-enabled biosimulation to improve strategic decision-making and success rates at every phase of drug development.”

The new offering combines strategic regulatory guidance with AI-enabled biosimulation, providing an ethical and efficient pathway through early-stage drug development. With adoption already underway, Certara’s platform offers a future-ready model for companies advancing biologics, including monoclonal antibodies and ADCs.

CareCloud, Inc. (NASDAQ: CCLD) has been named Maxim Group’s “Top Healthcare IT Pick for 2025,” with analysts citing the company’s AI-first strategy, strong financial performance, and discounted valuation as key drivers.

“AI is now deeply integrated into our operations—from documentation and revenue cycle management to patient engagement and analytics,” said Hadi Chaudhry, Co-CEO of CareCloud Inc. “This is not an add-on, it is a foundational capability that is changing how healthcare is delivered and experienced.”

The firm recently launched its AI Center of Excellence and introduced purpose-built tools like cirrusAI Notes and cirrusAI Voice to streamline clinical workflows and improve patient engagement. CareCloud plans to scale its AI team from 50 to 500 by year-end, deepening its role as a leader in applied healthcare AI.

Microsoft Corporation (NASDAQ: MSFT) has introduced its healthcare agent orchestrator—a multi-agent AI framework designed to support complex clinical workflows, such as tumor boards, by analyzing multimodal data across imaging, genomics, and electronic health records.

“The vision of the healthcare agent orchestrator is to rapidly surface, summarize, and take action on relevant multimodal medical information for each complex cancer case, so hours of review can become minutes,” said Dr. Joshua Warner, Radiologist at UW Health and Assistant Professor of Radiology, UW School of Medicine and Public Health. “Collaborating with Microsoft allows us to explore the value of these models for tumor boards and beyond.”

Now available through Azure AI Foundry, the system enables clinicians and developers to coordinate specialized AI agents directly within Microsoft Teams and Office tools, streamlining hours of expert analysis into minutes. Leading institutions like Stanford, Johns Hopkins, and Providence are already piloting the technology to accelerate cancer diagnosis, clinical trial matching, and treatment planning.

Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/   

Advertisement

CONTACT:

Equity Insider
[email protected]
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Video – https://mma.prnewswire.com/media/2695138/Equity_Insider.mp4
Logo – https://mma.prnewswire.com/media/2644233/5335696/Equity_Insider_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ai-could-add-461-billion-to-global-healthcareand-these-new-platforms-are-leading-the-charge-302464291.html